Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients
- 523 Downloads
To evaluate the diagnostic performance of breast-specific gamma imaging (BSGI) in the assessment of residual tumor after neoadjuvant chemotherapy (NAC) in breast cancer patients, female breast cancer patients who underwent NAC, preoperative 99mTc-sestamibi BSGI, and subsequent definitive breast surgery were enrolled retrospectively. The accuracy of BSGI in the assessment of residual tumor presence and residual tumor size was evaluated and compared to that of magnetic resonance imaging (MRI) using pathology results as the gold standard. The sensitivity and specificity of BSGI for residual tumor detection in 122 enrolled patients were 74.0 and 72.2 %, respectively, and were comparable to those of MRI (81.7 and 72.2 %; P > 0.100). The residual tumor size was significantly underestimated by BSGI in the luminal subtype (P = 0.008) and by MRI in the luminal (P < 0.001) and HER2 subtypes (P = 0.032), with a significantly lesser degree of underestimation by BSGI than MRI in both subtypes. In the triple-negative subtype, both BSGI and MRI generated accurate tumor size measurements. The residual cellularity of triple-negative tumors was significantly higher than that of the non-triple-negative tumors (P = 0.017). The diagnostic performance of BSGI in the assessment of residual tumor is comparable to that of MRI in breast cancer patients. The assessment of residual tumor extent by BSGI depends on the molecular subtype, but BSGI may be more accurate than MRI. Underestimation of tumor size in the luminal and/or HER2 subtypes by BSGI and MRI may be due to low-residual cellularity.
KeywordsBreast-specific gamma imaging Breast cancer Magnetic resonance imaging Neoadjuvant chemotherapy Residual tumor size
This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI06C0868).
Conflict of interest
The authors declare that they have no conflict of interest.
Experiments performed in this study comply with the current laws of the Republic of Korea.
- 4.Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96(6):474–480. doi: 10.1002/jso.20856 PubMedCrossRefGoogle Scholar
- 5.Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE (2006) Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257–264. doi: 10.1097/01.sla.0000197714.14318.6f00000658-200602000-00016 PubMedCentralPubMedCrossRefGoogle Scholar
- 6.Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30(10):1069–1076. doi: 10.1016/j.ejso.2004.07.024 PubMedCrossRefGoogle Scholar
- 8.Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY (2009) Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20(4):636–641. doi: 10.1093/annonc/mdn683 PubMedCrossRefGoogle Scholar
- 9.Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29(6):660–666. doi: 10.1200/JCO.2010.31.1258JCO.2010.31.1258 PubMedCrossRefGoogle Scholar
- 10.McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G (2011) MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18(11):3149–3154. doi: 10.1245/s10434-011-1912-z PubMedCrossRefGoogle Scholar
- 12.Spanu A, Chessa F, Meloni GB, Sanna D, Cottu P, Manca A, Nuvoli S, Madeddu G (2008) The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer. Clin Nucl Med 33(11):739–742. doi: 10.1097/RLU.0b013e318187ee7500003072-200811000-00001 PubMedCrossRefGoogle Scholar
- 15.Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G (2012) Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 15(2):203–210. doi: 10.4048/jbc.2012.15.2.203 PubMedCentralPubMedCrossRefGoogle Scholar
- 17.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi: 10.1093/annonc/mdr304 PubMedCentralPubMedCrossRefGoogle Scholar
- 18.Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzkowsky L, Weigert J, Heston TF, Jones E, Buscombe J, Stabin MG, Society of Nuclear M (2010) SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. J Nucl Med Technol 38(4):219–224. doi: 10.2967/jnmt.110.082271 PubMedCrossRefGoogle Scholar
- 19.Jin S, Kim SB, Ahn JH, Jung KH, Ahn SH, Son BH, Lee JW, Gong G, Kim HO, Moon DH (2013) 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study. J Surg Oncol 107(2):180–187. doi: 10.1002/jso.23255 PubMedCrossRefGoogle Scholar
- 21.Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422. doi: 10.1200/JCO.2007.10.6823 PubMedCrossRefGoogle Scholar
- 24.Larson M, Larson M, Li Z, Larson M, Li Z, Hall CL, Jensen E, McAllister DM, Kalyanaraman B, Zhao M (2009) Physiological fluctuation of (99m)Tc-sestamibi uptake in normal mammary glands: a systematic investigation in female rats. Acta Radiol 50(9):975–978. doi: 10.3109/02841850903134127 PubMedCrossRefGoogle Scholar
- 30.Keto JL, Kirstein L, Sanchez DP, Fulop T, McPartland L, Cohen I, Boolbol SK (2012) MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in situ: a prospective head-to-head trial. Ann Surg Oncol 19(1):249–252. doi: 10.1245/s10434-011-1848-3 PubMedCrossRefGoogle Scholar